• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Comparative analysis of SGLT-2 expression in renal vasculitis and lupus nephritis.

作者信息

Hakroush Samy, Tampe Desiree, Kluge Ingmar Alexander, Baier Eva, Korsten Peter, Tampe Björn

机构信息

Institute of Pathology, University Medical Center Göttingen, Göttingen, Germany.

Department of Nephrology and Rheumatology, University Medical Center Göttingen, Göttingen, Germany.

出版信息

Ann Rheum Dis. 2022 Jul;81(7):1048-1050. doi: 10.1136/annrheumdis-2022-222167. Epub 2022 Feb 25.

DOI:10.1136/annrheumdis-2022-222167
PMID:35217513
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9209668/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6cbe/9209668/0150f5fc1fc8/annrheumdis-2022-222167f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6cbe/9209668/0150f5fc1fc8/annrheumdis-2022-222167f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6cbe/9209668/0150f5fc1fc8/annrheumdis-2022-222167f01.jpg

相似文献

1
Comparative analysis of SGLT-2 expression in renal vasculitis and lupus nephritis.肾血管炎和狼疮性肾炎中SGLT-2表达的比较分析。
Ann Rheum Dis. 2022 Jul;81(7):1048-1050. doi: 10.1136/annrheumdis-2022-222167. Epub 2022 Feb 25.
2
Systemic lupus erythematosus: renal vasculitis. 2nd Seminar on Renal Involvement in Systemic Vasculitis. Vimercate, September 21, 1991.系统性红斑狼疮：肾血管炎。系统性血管炎肾受累第二次研讨会。维梅尔卡特，1991年9月21日。
Contrib Nephrol. 1992;99:1-152.
3
Correspondence on 'Call for action in ANCA-associated vasculitis and lupus nephritis: promises and challenges of SGLT-2 inhibitors'.关于“抗中性粒细胞胞浆抗体相关血管炎和狼疮性肾炎的行动呼吁：钠-葡萄糖协同转运蛋白2抑制剂的前景与挑战”的通信
Ann Rheum Dis. 2023 Aug;82(8):e195. doi: 10.1136/annrheumdis-2021-221953. Epub 2022 Jan 13.
4
Is renal vasculitis in patients with systemic lupus erythematosus a bad prognostic factor?系统性红斑狼疮患者的肾血管炎是不良预后因素吗？
Contrib Nephrol. 1992;99:72-8. doi: 10.1159/000421692.
5
Post-transplant immune complex nephritis in a patient with systemic lupus erythematosus associated with ANCA vasculitis.一名患有系统性红斑狼疮合并抗中性粒细胞胞浆抗体血管炎患者的移植后免疫复合物性肾炎。
Pediatr Transplant. 2017 May;21(3). doi: 10.1111/petr.12895. Epub 2017 Jan 29.
6
Lupus vasculitis.狼疮性血管炎
Contrib Nephrol. 1992;99:35-45. doi: 10.1159/000421687.
7
Bilateral retinal vasculitis presenting as the first manifestation of systemic lupus erythematosus: a case report.双侧视网膜血管炎作为系统性红斑狼疮的首发表现：一例病例报告
J Med Case Rep. 2025 Mar 21;19(1):132. doi: 10.1186/s13256-025-05158-6.
8
Renal vascular complications of systemic lupus erythematosus.系统性红斑狼疮的肾血管并发症。
J Am Soc Nephrol. 1994 Feb;4(8):1499-515. doi: 10.1681/ASN.V481499.
9
[Renal changes in systemic lupus erythematosus (lupus nephritis)].[系统性红斑狼疮的肾脏改变（狼疮性肾炎）]
Pol Tyg Lek. 1961 Nov 27;16:1853-7.
10
Elevated serum level of growth arrest-specific protein 6 (Gas6) in systemic lupus erythematosus patients is associated with nephritis and cutaneous vasculitis.系统性红斑狼疮患者血清中生长停滞特异性蛋白6（Gas6）水平升高与肾炎和皮肤血管炎相关。
Rheumatol Int. 2014 May;34(5):625-9. doi: 10.1007/s00296-013-2882-1. Epub 2013 Nov 1.

引用本文的文献

1
Weight gain following a diagnosis of anti-neutrophil cytoplasmic antibody-associated vasculitis.抗中性粒细胞胞浆抗体相关血管炎诊断后的体重增加
Rheumatol Adv Pract. 2025 Aug 9;9(3):rkaf088. doi: 10.1093/rap/rkaf088. eCollection 2025.
2
Advances in precision medicine for lupus nephritis: biomarker- and AI-driven diagnosis and treatment response prediction and targeted therapies.狼疮性肾炎精准医学的进展：生物标志物和人工智能驱动的诊断、治疗反应预测及靶向治疗
EBioMedicine. 2025 Jun 3;117:105785. doi: 10.1016/j.ebiom.2025.105785.
3
Progress of SGLT2 inhibitors in the treatment of common immune-related nephropathies.

本文引用的文献

1
Response to: Correspondence on 'Call for action in ANCA-associated vasculitis and lupus nephritis: promises and challenges of SGLT-2 inhibitors' by Patoulias.对帕图利亚斯就“抗中性粒细胞胞浆抗体相关性血管炎和狼疮性肾炎的行动呼吁：钠-葡萄糖协同转运蛋白2抑制剂的前景与挑战”的通信的回复
Ann Rheum Dis. 2023 Aug;82(8):e196. doi: 10.1136/annrheumdis-2021-221982. Epub 2022 Jan 13.
2
Correspondence on 'Call for action in ANCA-associated vasculitis and lupus nephritis: promises and challenges of SGLT-2 inhibitors'.关于“抗中性粒细胞胞浆抗体相关血管炎和狼疮性肾炎的行动呼吁：钠-葡萄糖协同转运蛋白2抑制剂的前景与挑战”的通信
Ann Rheum Dis. 2023 Aug;82(8):e195. doi: 10.1136/annrheumdis-2021-221953. Epub 2022 Jan 13.
3
SGLT2 抑制剂在治疗常见免疫相关性肾炎中的研究进展。
Int Urol Nephrol. 2024 Dec;56(12):3807-3813. doi: 10.1007/s11255-024-04141-2. Epub 2024 Jul 4.
4
A Transcriptome Array-Based Approach to Link SGLT-2 and Intrarenal Complement C5 Synthesis in Diabetic Nephropathy.基于转录组芯片的方法探讨糖尿病肾病中 SGLT-2 和肾内补体 C5 合成的关系。
Int J Mol Sci. 2023 Dec 2;24(23):17066. doi: 10.3390/ijms242317066.
5
Lupus Nephritis: New and Emerging Biologic and Targeted Therapies.狼疮性肾炎：新型及新兴生物制剂和靶向治疗药物。
BioDrugs. 2023 Jul;37(4):463-475. doi: 10.1007/s40259-023-00597-3. Epub 2023 Apr 24.
6
Safety and efficacy of the SGLT2 inhibitor dapagliflozin in patients with systemic lupus erythematosus: a phase I/II trial.SGLT2 抑制剂达格列净在系统性红斑狼疮患者中的安全性和疗效：一项 I/II 期试验。
RMD Open. 2022 Oct;8(2). doi: 10.1136/rmdopen-2022-002686.
Call for action in ANCA-associated vasculitis and lupus nephritis: promises and challenges of SGLT-2 inhibitors.
呼吁在抗中性粒细胞胞浆抗体相关性血管炎和狼疮性肾炎中采取行动：SGLT-2 抑制剂的前景与挑战。
Ann Rheum Dis. 2022 May;81(5):614-617. doi: 10.1136/annrheumdis-2021-221474. Epub 2021 Nov 29.
4
Dapagliflozin in Patients with Chronic Kidney Disease.达格列净治疗慢性肾脏病患者。
N Engl J Med. 2020 Oct 8;383(15):1436-1446. doi: 10.1056/NEJMoa2024816. Epub 2020 Sep 24.
5
Renal SGLT mRNA expression in human health and disease: a study in two cohorts.人类健康和疾病中的肾脏 SGLT mRNA 表达：两项队列研究。
Am J Physiol Renal Physiol. 2019 Nov 1;317(5):F1224-F1230. doi: 10.1152/ajprenal.00370.2019. Epub 2019 Sep 23.
6
Tissue transcriptome-driven identification of epidermal growth factor as a chronic kidney disease biomarker.基于组织转录组学驱动鉴定表皮生长因子作为慢性肾脏病生物标志物
Sci Transl Med. 2015 Dec 2;7(316):316ra193. doi: 10.1126/scitranslmed.aac7071.